DW-4321

DW-4321 is a preclinical-stage small molecule quadruple agonist being developed by Daewon Pharm in collaboration with Asan Medical Center for the treatment of obesity. As a quadruple agonist, the compound is designed to simultaneously activate four distinct biological pathways involved in metabolic regulation and energy homeostasis. While the specific targets have not been publicly disclosed by the developer, the program aims to provide a potent weight-loss therapy with the potential advantages of a small molecule modality, such as oral bioavailability, compared to existing peptide-based multi-agonists. The drug is currently undergoing preclinical evaluation to establish its safety and efficacy profile.

Other names

DW-4321DW4321DW 4321